Lenumlostat

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160691

2098884-52-5

C160691

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

An orally available, small-molecule, irreversible inhibitor of lysyl oxidase homolog 2 (lysyl oxidase-like protein 2; LOXL2) with potential antifibrotic activity. Upon oral administration, the aminomethyl pyridine moiety of lenumlostat interacts with the active site of LOXL2 to form a pseudo-irreversible inhibitory complex, thereby inhibiting the catalytic activity of LOXL2. LOXL2, a secreted glycoprotein, catalyzes the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, leading to the formation of deaminated lysine (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages that impact remodeling of the extracellular matrix (ECM), potentially leading to fibrosis. Inhibition of LOXL2, which is often upregulated in fibrotic tissue, may reduce fibrosis in certain chronic fibrotic diseases.

Lenumlostat

Y3HMF6G24B

Lenumlostat

LENUMLOSTAT

Lysyl Oxidase-like Protein 2 Inhibitor PAT-1251

LOXL2 Inhibitor GB2064

GB2064

GB 2064

GB-2064

PAT-1251

PAT1251

PAT 1251

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C95874

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Lenumlostat

LOXL2 Inhibitor PAT-1251

800789

CL969613

800789

800789

Lenumlostat

Thesaurus:C160691

Lenumlostat

Pharmacologic Substance

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C471